Efficacy of brexpiprazole on caregiver‐identified bothersome agitation symptoms that influence the decision to transfer to long‐term care: a 24‐week <i>post hoc</i> analysis of patients with dementia due to Alzheimer’s disease

Treatment with brexpiprazole 2 or 3 mg/day over 24 weeks was associated with continued and sustained benefits on agitation symptoms that are considered most bothersome to caregivers, and that influence caregiver decisions to transfer patients to long-term care.